These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10346425)

  • 1. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines.
    McKenney JM
    Pharmacoeconomics; 1998; 14 Suppl 3():19-28. PubMed ID: 10346425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource utilisation in the management of dyslipidaemia.
    Szucs TD
    Pharmacoeconomics; 1998; 14 Suppl 3():11-8. PubMed ID: 10346424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
    J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for aggressive lipid lowering in high-risk patients.
    Cohen JD
    J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
    Davidson MH; Maki KC; Pearson TA; Pasternak RC; Deedwania PC; McKenney JM; Fonarow GC; Maron DJ; Ansell BJ; Clark LT; Ballantyne CM
    Am J Cardiol; 2005 Aug; 96(4):556-63. PubMed ID: 16098311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
    Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
    Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The human and economic costs of undertreatment with statins.
    Durrington P
    Int J Clin Pract; 2002 Jun; 56(5):357-68. PubMed ID: 12137445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Cholesterol Education Panel III guidelines performance role in preventing myocardial infarction in a large cohort without a history of coronary artery disease: Korea Acute Myocardial Infarction Registry study.
    Yoon YE; Rivera JJ; Kwon DA; Chae IH; Jeong MH; Rha SW; Blumenthal RS; Nasir K; Chang HJ;
    Prev Cardiol; 2009; 12(2):109-13. PubMed ID: 19476585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications.
    Keenan JM
    South Med J; 2003 Mar; 96(3):266-75. PubMed ID: 12659359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering interventions in managed care settings.
    Fox J; Jones K
    Am J Med; 2001 Apr; 110 Suppl 6A():24S-30S. PubMed ID: 11311194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.